PremiumThe FlyScotiabank downgrades Myriad Genetics, sees ‘transitional year’ ahead Myriad Genetics downgraded to Sector Perform from Outperform at Scotiabank Myriad Genetics price target lowered to $4 from $9 at BofA PremiumThe FlyMyriad Genetics downgraded to Peer Perform from Outperform at Wolfe Research China announces stimulus measures, Disney reports Q2 beat: Morning Buzz Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum PremiumCompany AnnouncementsMyriad Genetics Reports Mixed Q1 2025 Results Myriad Genetics Faces Revenue Declines and Strategic Challenges: Hold Rating Maintained Myriad Genetics cuts FY25 adjusted EPS view to (2c)-2c from 7c-11c 
